2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal
BORN, G. V. R. (1962) · Nature · doi:10.1038/194927b0 · Cited by 4,294
Moncada, S., Gryglewski, R., Bunting, S., & Vane, J. R. (1976) · Nature · doi:10.1038/263663a0 · Cited by 3,595 · cited 2×
“PGI2, which is mainly produced in vascular endothelial cells (Moncada et al., 1976; Moncada and Vane, 1978), acts via the PGI2 receptor (IP receptor) as a potent vasodilator and inhibitor of platelet aggregation (Namba et al.”
BackgroundBarst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698 · cited 4×
“For example, although intravenous infusion of PGI2 can improve exercise tolerance and survival in patients with pulmonary arterial hypertension (Barst et al., 1996), this therapy requires a complicated delivery system for continuous infusion through a central venous catheter because of its very short half-life (3–5 mi…”
BackgroundInfluentialProstanoid Receptors: Structures, Properties, and Functions
Narumiya, S., Sugimoto, Y., & Ushikubi, F. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1193 · Cited by 2,412 · cited 3×
“1181 fects in many organ systems, for example, the regulation of tissue blood flow, inhibition of thrombus formation, inhibition of the growth of smooth muscle cells, and protection of vascular endothelial cells (Narumiya et al., 1999).”
BackgroundTreatment of Pulmonary Arterial Hypertension
Humbert, M., Sitbon, O., & Simonneau, G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040291 · Cited by 1,707 · cited 2×
“A more serious complication of this treatment is the incidence of catheter-related sepsis (Humbert et al., 2004).”
BackgroundPharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.
Moncada, S., & Vane, J. R. (1978) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06759-6 · Cited by 1,576 · cited 3×
“Although beneficial clinical effects of PGI2 were expected (Armstrong, 1996), PGI2 itself is too unstable (Moncada and Vane, 1978) for widespread clinical application.”
BackgroundProstanoid Receptors: Subtypes and Signaling
Breyer, R. M., Bagdassarian, C. K., Myers, S. A., & Breyer, M. D. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.661 · Cited by 1,011 · cited 1×
“These lipid mediators interact with specific G protein-coupled receptors (DP, EP1, EP2, EP3, EP4, FP, IP, and TP) and activate the corresponding intracellular signaling cascade (Narumiya et al., 1999; Breyer et al., 2001).”
BackgroundTUDER, R. M., COOL, C. D., GERACI, M. W., WANG, J., ABMAN, S. H., WRIGHT, L., BADESCH, D., & VOELKEL, N. F. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.6.9804054 · Cited by 806 · cited 2×
“A decrease in PGI2 production or an imbalance between PGI2 and TXA2 has been reported in several diseases such as pulmonary arterial hypertension (Tuder et al., 1999), ischemic vascular disease (Hirsh et al.”
BackgroundAltered pain perception and inflammatory response in mice lacking prostacyclin receptor
Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., Ichikawa, A., Aze, Y., Tanaka, T., Yoshida, N., et al. (1997) · Nature · doi:10.1038/41780 · Cited by 773 · cited 1×
“Studies on IP receptor-deficient mice have clarified the role of the PGI2-IP system, and we now know that IP receptor deficiency induces thrombus formation and reduces inflammatory and pain responses (Murata et al., 1997).”
BackgroundAbramovitz, M., Adam, M., Boie, Y., Carrière, M.-C., Denis, D., Godbout, C., Lamontagne, S., Rochette, C., Sawyer, N., Tremblay, N. M., et al. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00164-x · Cited by 557 · cited 3×
“MRE-269 showed a high binding affinity for the human IP receptor, with a Ki value of 20 nM, so that it is as potent as various PGI2 analogs such as beraprost (Ki 39 nM in the present study), iloprost (Ki 11 nM), and cicaprost (Ki 17 nM) (Abramovitz et al., 2000).”
BackgroundInfluential
Cited by
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Sitbon, O., Channick, R., Chin, K. M., Frey, A., Gaine, S., Galiè, N., Ghofrani, H.-A., Hoeper, M. M., Lang, I. M., Preiss, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503184 · Cited by 1,060
Pulmonary Arterial Hypertension
McLaughlin, V. V., & McGoon, M. D. (2006) · Circulation · doi:10.1161/circulationaha.104.503540 · Cited by 664
Woodward, D. F., Jones, R. L., & Narumiya, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003517 · Cited by 443
Endothelium‐mediated control of vascular tone: COX‐1 and COX‐2 products
Félétou, M., Huang, Y., & Vanhoutte, P. M. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01276.x · Cited by 372
Simonneau, G., Torbicki, A., Hoeper, M. M., Delcroix, M., Karlócai, K., Galiè, N., Degano, B., Bonderman, D., Kurzyna, M., Efficace, M., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00137511 · Cited by 314
Pulmonary arterial hypertension
Montani, D., Günther, S., Dorfmüller, P., Perros, F., Girerd, B., Garcia, G., Jaïs, X., Savale, L., Artaud-Macari, E., Price, L. C., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-97 · Cited by 314
Targeted therapies in pulmonary arterial hypertension
Montani, D., Chaumais, M.-C., Guignabert, C., Günther, S., Girerd, B., Jaïs, X., Algalarrondo, V., Price, L. C., Savale, L., Sitbon, O., et al. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.002 · Cited by 213
“most commonly reported adverse event (Kuwano et al., 2007).”
MethodWhittle, B. J., Silverstein, A. M., Mottola, D. M., & Clapp, L. H. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.03.012 · Cited by 168
A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension
Mubarak, K. K. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2009.07.015 · Cited by 165
Pathways in pulmonary arterial hypertension: the future is here
Sitbon, O., & Morrell, N. (2012) · European Respiratory Review · doi:10.1183/09059180.00004812 · Cited by 117
Metadata
- Authors
- Kuwano, K., Hashino, A., Asaki, T., Hamamoto, T., Yamada, T., Okubo, K., & Kuwabara, K.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 322
- Issue
- 3
- Pages
- 1181-1188
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2136124268
- Cited by
- 164
- References
- 22
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.